This report presents two cases of penicillium marneffei infection occurring after kidney transplantation. Both recipients presented initially with gastrointestinal symptoms and were diagnosed early by metagenomic next generation sequencing (mNGS). Treatment included amphotericin B combined with voriconazole, adjustment of immunosuppressive therapy, and nutritional support, resulting in favorable outcomes. This study aims to characterize the clinical presentation, diagnostic challenges, and individualized treatment strategies for penicillium marneffei infection in kidney transplant recipients, providing valuable insights for clinical management.

Kidney transplantation is an effective treatment for end-stage renal disease.However,post transplantation diabetes mellitus(PTDM)is a common complication after kidney transplantation,affecting 10%to 40%of recipients and increasing the risk of cardiovascular disease,infections,sepsis and other conditions.The pathogenesis of PTDM is complex,including pancreatic β-cell dysfunction and insulin resistance.Tacrolimus,a commonly used immunosuppressive drug,is an independent risk factor for PTDM.Its mechanisms include damaging pancreatic β-cells,mediating impaired mitochondrial autophagy,etc.In addition,tacrolimus also raises blood glucose levels through various pathways,such as affecting gut microbiota metabolism and activating bile acid signaling pathways.In recent years,some new anti-diabetic drugs have shown certain application prospects in kidney transplant recipients,but the evidence-based medical evidence for their combined use still needs further exploration.In the future,it is necessary to conduct in-depth research on the multiple sites of action of tacrolimus to reduce the occurrence of PTDM and improve the prognosis of kidney transplant recipients.

Talaromyces marneffei is a rare opportunistic pathogen.Talaromyces marneffei infection is characterized by insidious onset,atypical clinical manifestations,low early diagnosis rate,and high misdiagnosis and fatality,and has received widespread attention in recent years.Organ transplant recipients become a high-risk group for Talaromyces marneffei infection due to postoperative immunosuppressive therapy.Metagenomic next-generation sequencing,targeted antifungal therapy,and immunosuppression regimen adjustment are key to improving the prognosis of Talaromyces marneffei infection patients.This article reviews the epidemiology,pathogenesis,diagnosis and treatment of Talaromyces marneffei infection in organ transplant recipients,explores current challenges and future research directions,and aims to inform the diagnosis and treatment of Talaromyces marneffeiinfection.

Kidney transplantation is an effective treatment for end-stage renal disease.However,post transplantation diabetes mellitus(PTDM)is a common complication after kidney transplantation,affecting 10%to 40%of recipients and increasing the risk of cardiovascular disease,infections,sepsis and other conditions.The pathogenesis of PTDM is complex,including pancreatic β-cell dysfunction and insulin resistance.Tacrolimus,a commonly used immunosuppressive drug,is an independent risk factor for PTDM.Its mechanisms include damaging pancreatic β-cells,mediating impaired mitochondrial autophagy,etc.In addition,tacrolimus also raises blood glucose levels through various pathways,such as affecting gut microbiota metabolism and activating bile acid signaling pathways.In recent years,some new anti-diabetic drugs have shown certain application prospects in kidney transplant recipients,but the evidence-based medical evidence for their combined use still needs further exploration.In the future,it is necessary to conduct in-depth research on the multiple sites of action of tacrolimus to reduce the occurrence of PTDM and improve the prognosis of kidney transplant recipients.

Talaromyces marneffei is a rare opportunistic pathogen.Talaromyces marneffei infection is characterized by insidious onset,atypical clinical manifestations,low early diagnosis rate,and high misdiagnosis and fatality,and has received widespread attention in recent years.Organ transplant recipients become a high-risk group for Talaromyces marneffei infection due to postoperative immunosuppressive therapy.Metagenomic next-generation sequencing,targeted antifungal therapy,and immunosuppression regimen adjustment are key to improving the prognosis of Talaromyces marneffei infection patients.This article reviews the epidemiology,pathogenesis,diagnosis and treatment of Talaromyces marneffei infection in organ transplant recipients,explores current challenges and future research directions,and aims to inform the diagnosis and treatment of Talaromyces marneffeiinfection.

This report presents two cases of penicillium marneffei infection occurring after kidney transplantation. Both recipients presented initially with gastrointestinal symptoms and were diagnosed early by metagenomic next generation sequencing (mNGS). Treatment included amphotericin B combined with voriconazole, adjustment of immunosuppressive therapy, and nutritional support, resulting in favorable outcomes. This study aims to characterize the clinical presentation, diagnostic challenges, and individualized treatment strategies for penicillium marneffei infection in kidney transplant recipients, providing valuable insights for clinical management.

Objective:To apply real-time shear wave elastography to observe the effect of instrument-assisted soft tissue mobilization (IASTM) on Achilles tendons for healthy adults. Methods:From July to December, 2020, 52 healthy adults were assigned into control group (n = 15) and experimental group (n = 37) randomly. The experimental group received IASTM on left Achilles tendons, once another day for two weeks, while the control group received no treatment. The thickness and elastic modulus of the left Achilles tendons were measured with high-frequency ultrasound and shear wave ultrasound elastography on all the subjects, before treatment, immediately after the first treatment and three days after treatment, respectively. Results:Five cases dropped down in the experimental group. There was no significant difference in thickness and elastic Young's modulus of the left Achilles tendons between two groups before treatment (t < 0.630, P > 0.05). The thickness of the left Achilles tendons was less in the experimental group than in the control group immediately after the first treatment (t = 2.149, P < 0.05), while average and maximum elastic Young's modulus was less three days after treatment (t > 2.134, P < 0.05). Conclusion:Real-time shear wave elastography could quantify the thickness and elasticity of Achilles tendon, to evaluate the effect of IASTM.